Madrigal Pharmaceuticals, Inc.
A maker of Rezdiffra, the first FDA-approved drug for MASH, a fatty-liver disease that can lead to serious liver damage. Founded in 2011 by Dr. Rebecca Taub to develop a thyroid-hormone molecule she had rediscovered, the company took its name from the madrigal, a Renaissance choral song, as a nod to restoring harmony to the liver. Fun quirk: it's unrelated to the fictional Madrigal Electromotive from Breaking Bad.
Granted 7.5K · Bought 590.4K
Granted 201.1K · Sold 196.1K
Granted 357.3K · Sold 355.9K
Granted 38.7K · Sold 45.0K
Granted 190.3K · Sold 28.5K
Granted 47.4K · Sold 35.2K
Granted 4.8K
Granted 13.4K · Sold 9.8K
Granted 13.2K · Sold 9.6K
Granted 18.8K · Sold 6.2K
Granted 12.4K · Sold 3.0K
Granted 29.3K · Sold 28.6K
Granted 11.9K · Sold 1.9K
Granted 80.5K · Sold 79.1K
Granted 49.8K · Sold 48.0K
Granted 2.4K
Granted 1.6K
Granted 1.4K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Baker Bros. Advisors LP +5 co-filersDirector · 198 transactions | — | 4.09M | 7.5K | 590.4K | — |
| Taub RebeccaDirector · 108 transactions | +64% | 1.11M | 201.1K | — | 196.1K |
| Friedman Paul ADirector · 119 transactions | +26.7% | 855.9K | 357.3K | — | 355.9K |
| Craves Fred BDirector · 38 transactions | — | 753.9Kas of Mar 2025 | 38.7K | — | 45.0K |
| Sibold William JohnPresident and CEO, Director · 14 transactions | — | 161.8K | 190.3K | — | 28.5K |
| Levy Richard SDirector · 49 transactions | +118.2% | 22.5K | 47.4K | — | 35.2K |
| Howarth Alex G.Chief Financial Officer · 2 transactions | +24.9% | 18.7Kas of Jan 2024 | 4.8K | — | — |
| Lynch Brian JosephSVP and General Counsel · 15 transactions | +17.3% | 18.2Kas of Jan 2024 | 13.4K | — | 9.8K |
| Dier MardiEVP and CFO · 34 transactions | — | 12.8K | 13.2K | — | 9.6K |
| Huntsman CaroleChief Commercial Officer · 29 transactions | — | 12.7K | 18.8K | — | 6.2K |
| Kelley Shannon TGeneral Counsel · 16 transactions | — | 12.1K | 12.4K | — | 3.0K |
| Waltermire Robert E.Senior VP, Chief Pharma Dev. · 35 transactions | +2.4% | 10.9Kas of Mar 2025 | 29.3K | — | 28.6K |
| Soergel DavidChief Medical Officer · 4 transactions | — | 10.0K | 11.9K | — | 1.9K |
| Bate KennethDirector · 56 transactions | +642.6% | 8.9K | 80.5K | — | 79.1K |
| Daly James MDirector · 27 transactions | +157.2% | 3.1K | 49.8K | — | 48.0K |
| Thakkar RitaChief Accounting Officer · 1 transaction | — | 2.4K | 2.4K | — | — |
| Fouse Jacqualyn ADirector · 3 transactions | — | 1.6K | 1.6K | — | — |
| Brennan Daniel J.Director · 2 transactions | — | 1.4K | 1.4K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: -256.3K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.